CD44 and breast carcinoma: In breast cancer, for example, the CD44+/CD24− phenotype combined with elevated ALDH activity has been widely adopted to isolate highly tumorigenic and therapy-resistant CSC subsets.197 This combination not only improves the enrichment of CSCs but also correlates with clinical outcomes, including recurrence and metastasis.